Skip to main content

The independent medical news service

Lung cancer

19-09-2021 | Oncology | News | Article

Trastuzumab deruxtecan supported for pretreated HER2-mutant NSCLC

Trastuzumab deruxtecan achieves durable responses in individuals who have received prior treatment for metastatic non-small-cell lung cancer harboring HER2 mutations, suggests the DESTINY-Lung01 trial.

18-09-2021 | Oncology | News | Article

COAST points to potential of durvalumab combinations in stage III NSCLC

Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

17-09-2021 | Oncology | News | Article

FDA approves mobocertinib for advanced NSCLC with EGFR exon 20 insertions

Click through to read more about this approval

15-09-2021 | Oncology | News | Article

No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

14-09-2021 | Oncology | News | Article

Flexibility positively impacts lung cancer clinical trial participation in COVID-19 era

Strategies to improve flexibility in clinical trials may improve enrollment rates during and after the COVID-19 pandemic, according to a study presented at the IASLC 2021 World Conference on Lung Cancer.

13-09-2021 | Oncology | News | Article

​​​​​​​Pretreatment ctDNA levels may predict survival in neoadjuvant-treated NSCLC patients

Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.

13-09-2021 | Oncology | News | Article

Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.

10-09-2021 | Oncology | News | Article

No OS benefit of lurbinectedin plus doxorubicin in relapsed SCLC

The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.

09-09-2021 | Oncology | News | Article

Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

07-09-2021 | Oncology | News | Article

Single-fraction SABR may be preferred for lung oligometastases

Stereotactic ablative body radiotherapy offers similar outcomes, in terms of toxicity and efficacy, whether it is given as a single fraction or in multiple fractions to patients with up to three lung oligometastases, SAFRON II trial data show.

06-09-2021 | Oncology | News | Article

Significant declines in cancer diagnoses during first year of COVID-19 pandemic

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

02-09-2021 | Oncology | News | Article

Chemoimmunotherapy efficacy unaffected by antibiotic use in advanced NSCLC

Antibiotic use does not impair the survival of patients with metastatic non-small-cell lung cancer treated with first-line chemoimmunotherapy, suggest results from an international retrospective study.

20-08-2021 | Oncology | News | Article

Hypofractionated image-guided RT not the answer for chemoradiotherapy-ineligible NSCLC

Hypofractionated image-guided radiotherapy does not improve survival relative to conventional radiotherapy in patients with stage II or III non-small-cell lung cancer ineligible for concurrent chemoradiotherapy, research shows.

16-08-2021 | Oncology | News | Article

Pan-cancer survival hope with individualized radiotherapy approach

Study findings suggest that using a genomic-adjusted radiation dose may help overcome the heterogeneity of tumor response to radiotherapy and improve overall survival for patients with cancer.

11-08-2021 | Oncology | News | Article

Antibody response to COVID-19 vaccination appears durable in people with cancer

The seropositivity rate in response to the Pfizer–BioNTech (BNT162b2) vaccine against SARS-CoV-2 remains high around 4 months after the second dose in cancer patients undergoing active therapy, report Israeli researchers.

05-08-2021 | Oncology | News | Article

Add-on metformin fails to improve locally advanced NSCLC outcomes

Nondiabetic patients with stage III non-small-cell lung cancer do not benefit from the addition of metformin to chemoradiotherapy, suggest results from two phase 2 trials.

30-07-2021 | Oncology | News | Article

No survival benefit with second-line ipilimumab plus nivolumab in advanced squamous NSCLC

The addition of ipilimumab to nivolumab does not improve the survival outcomes of patients with advanced squamous non-small-cell cancer who have previously received chemotherapy, shows the phase 3 LUNG-MAP S1400I trial.

27-07-2021 | Oncology | News | Article

Quitting smoking after lung cancer diagnosis improves survival outcomes

Smokers who quit after receiving a diagnosis of early-stage non-small-cell lung cancer significantly improve their likelihood of survival relative to those who continue smoking, shows a large prospective cohort study.

22-07-2021 | Oncology | News | Article

Savolitinib responses encouraging in MET exon 14-mutated NSCLC

Phase 2 study results indicate that savolitinib has promising antitumor activity in Chinese patients with non-small-cell lung cancer harboring MET exon 14 skipping alterations, including those with pulmonary sarcomatoid carcinoma.

19-07-2021 | Oncology | News | Article

Perioperative durvalumab addition promising for stage IIIA NSCLC

Adding perioperative durvalumab to neoadjuvant chemotherapy could be a feasible option for patients with resectable, locally advanced non-small-cell lung cancer with mediastinal lymph node involvement, suggest phase 2 trial data.

Image Credits